This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
Gilead (GILD) Q1 Earnings & Sales Miss Estimates on Weak HCV
by Zacks Equity Research
Gilead (GILD) announced dismal results for the first-quarter as HCV sales plunged further due to increasing competition.
Drug Stocks Q1 Earnings to Watch on May 1: PFE, MRK & More
by Zacks Equity Research
Four pharma/biotech companies are set to release earnings report on May 1. Let's take a look into how the companies are placed ahead of the upcoming results.
HIV Segment to Aid Gilead (GILD) Beat Q1 Earnings Estimates?
by Zacks Equity Research
Gilead (GILD) is likely to report an earnings beat in the first-quarter (results due on May 1) driven by its HIV franchise strength.
DaVIta (DVA) to Report Q1 Earnings: Is a Beat in Store?
by Zacks Equity Research
Kidney Care Business and increasing number of dialysis centers are likely to boost DaVita's (DVA) earnings in Q1.
AbbVie (ABBV) Q1 Earnings Beat, 2018 View Up, Stock Gains
by Zacks Equity Research
AbbVie's (ABBV) Q1 earnings top estimates with revenues marginally beating the same. Sales of the company's lead marketed drug, Humira, also rise year over year.
Is a Beat in the Cards for Gilead (GILD) in Q1 Earnings?
by Zacks Equity Research
Gilead (GILD) is likely to beat earnings estimates when it reports first-quarter results on May 1 driven by strong HIV sales.
AbbVie (ABBV) Tops Q1 Earnings and Revenues, View Up
by Debapriya Chakraborty
AbbVie's (ABBV) first-quarter 2018 earnings surpassed estimates with revenues marginally beating the same. Sales of its lead marketed drug Humira also increased compared to year ago figure.
What's in the Cards for Inogen (INGN) This Earnings Season?
by Zacks Equity Research
Inherent benefits of POCs, direct-to-customer business model, underpenetrated international markets and expanding product portfolio are key growth catalysts for Inogen (INGN) in Q1.
Drug Stock Q1 Earnings Due on Apr 26: ABBV, ALXN, BMY & VRTX
by Zacks Equity Research
Four pharma/biotech companies are set to release earnings report on Apr 26. Let's take a look into how the companies are placed ahead of the upcoming results.
Is a Beat in the Cards for AbbVie (ABBV) in Q1 Earnings?
by Zacks Equity Research
Impressive sales rise of AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company to an earnings beat in Q1.
Biogen (BIIB) Q1 Earnings Beat, Sales Miss, Shares Down
by Zacks Equity Research
Biogen's (BIIB) earnings beat estimates but sales miss the same marginally in Q1. The company's latest key drug Spinraza's tepid sales compares with its sequential tally.
What's in Store for AmerisourceBergen (ABC) in Q2 Earnings?
by Zacks Equity Research
Despite solid prospects in the Pharmaceutical Distribution segment, a temporary slowdown in the PharMEDium unit is likely to mar AmerisourceBergen's (ABC) Q2 earnings.
Can PBM Unit Boost Express Scripts' (ESRX) Q1 Earnings?
by Zacks Equity Research
Impressive performance by the PBM unit is likely to drive Express Scripts' (ESRX) Q1 earnings.
What Lies Ahead for Vice ETFs?
by Zacks Equity Research
Vice ETFs, which aim to profit from companies involved in alcohol, tobacco or gambling, are gathering steam.
Is a Beat in Store for Alexion (ALXN) This Earnings Season?
by Zacks Equity Research
Impressive sales of Alexion's blockbuster drug, Soliris might lead the company toward an earnings beat in Q1.
Q1 Earnings Surprise Well in Cards: Healthcare ETFs to Buy
by Sweta Killa
Let's dig into the earnings picture of the companies that would drive the performance of the popular health care ETFs in the coming days.
Will Global Industrial Unit Boost Ecolab's (ECL) Q1 Earnings?
by Zacks Equity Research
Solid prospects in Global Industrial, Global Energy and Global Institutional segments are likely to drive Ecolab's (ECL) Q1 earnings.
Is a Beat in Store for Bristol-Myers (BMY) in Q1 Earnings?
by Zacks Equity Research
Bristol-Myers (BMY) is scheduled to report Q1 earnings on Apr 26.
J&J, Novartis' Q1 Earnings Impress: Will Others Follow Suit?
by Zacks Equity Research
Johnson & Johnson (JNJ) and Novartis reported strong first-quarter 2018 earnings results earlier this week.
Roche Hemophilia Drug Gets Breakthrough Therapy Designation
by Zacks Equity Research
The FDA grants Breakthrough Therapy Designation to Roche's (RHHBY) Hemlibra for treatment of people with hemophilia A without factor VIII inhibitors.
The Zacks Analyst Blog Highlights: AbbVie, Berkshire Hathaway, PepsiCo, BP and Twenty-First Century Fox
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AbbVie, Berkshire Hathaway, PepsiCo, BP and Twenty-First Century Fox
5 Drug Stocks Poised to Surpass on Earnings This Quarter
by Zacks Equity Research
The outlook for the upcoming first-quarter results looks bright.
J&J (JNJ) Tops Q1 Earnings Estimates, Raises Sales Guidance
by Zacks Equity Research
J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2018. It maintains the previously issued earnings guidance for 2018 while increasing the sales range.
Shire Sells Oncology Unit Ahead of Takeda's Potential Offer
by Zacks Equity Research
Shire (SHPG) sells its oncology segment to France-based Servier for $2.4 billion. Takeda remains on track to make a potential offer for Shire.
Is J&J's (JNJ) Pharma Segment Likely to Drive Q1 Earnings?
by Zacks Equity Research
The positive trend seen in J&J's (JNJ) pharma segment sales in the second half of 2017 is likely to continue in Q1.